. 2020 Nov 27;303(6):1557–1567. doi: 10.1007/s00404-020-05883-x

Table 4.

TP53 mutation prevalence in families with female breast cancer only

Familial cancer history (including proband)	Total N	% of total	TP 53 mut* N	Prev %	TP53 VUS N	Prev %
I. Total cohort	1876		11	0.6%	20	1.1%
II. GROUP A: female unilateral breast cancer cases only (bBC, mBC, and OC excluded)	1639	87.4%	5	0.3%	14	0.9%
III. GROUP B: female BC, of these > 1bBC (mBC and OC excluded)	366	21.3%	4	1.1%	5	1.4%

Familial cancer history (including proband)

Total
N

% of total

TP 53 mut*
N

Prev %

TP53 VUS
N

Prev %

I. Total cohort

1876

0.6%

1.1%

II. GROUP A: female unilateral breast cancer cases only (bBC, mBC, and OC excluded)

1639

87.4%

0.3%

0.9%

III. GROUP B: female BC, of these > 1bBC

(mBC and OC excluded)

366

21.3%

1.1%

1.4%

bBC bilateral breast cancer disease; mBC male breast cancer disease; OC ovarian cancer; Prev Prevalence

*TP53 mut: including (likely) pathogenic TP53g mutations